Summary
Digitalis, diuretics, and vasodilators are considered standard therapy for patients with congestive heart failure, for which treatment is tailored according to the severity of the syndrome and the patient profile. Apart from the clinical seriousness, heart failure is always characterized by an energy depletion status, as indicated by low intramyocardial ATP and coenzyme Q10 levels. We investigated safety and clinical efficacy of coenzyme Q10 (CoQ10) adjunctive treatment in congestive heart failure, which had been diagnosed at least 6 months previously and treated with standard therapy. A total of 2500 patients in NYHA classes II and III were enrolled in this open noncomparative 3-month postmarketing drug surveillance study in 173 Italian centers. The daily dose of CoQ10 was 50–150 mg orally, with the majority of patients (78%) receiving 100 mg/day. Clinical and laboratory parameters were evaluated at the entry into the study and on day 90; the assessment of clinical signs and symptoms was made using from two- to seven-point scales. Preliminary results on 1113 patients (mean age 69.5 years) show a low incidence of side effects: 10 adverse reactions were reported in 8 (0.8%) patients, of which only 5 reactions were considered as correlated to the test treatment. After 3 months of test treatment the proportions of patients with improvement in clinical signs and symptoms were as follows: cyanosis 81%, edema 76.9%, pulmonary rales 78.4%, enlargement of the liver area 49.3%, jugular reflux 81.5%, dyspnea 54.2%, palpitations 75.7%, sweating 82.4%, arrhythmia 62%, insomnia 60.2%, vertigo 73%, and nocturia 50.7%. Moreover, we observed a contemporary improvement of at least three symptoms in 54% of patients; this could be interpreted as an index of improved quality of life.
Similar content being viewed by others
Abbreviations
- CoQ10 :
-
coenzyme Q10
- NYHA:
-
New York Heart Association
References
Colin Forfar J (1991) Neuroendocrine activation in congestive heart failure. Am J Cardiol 67:3C–5C
Crane PL, Hatefi Y, Lester RL, Widmer C (1957) Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 25:220–221
Digiesi V, Cantini F, Brodbeck B (1990) Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res Clin Exp 47:841–845
Digiesi V, Cantini F, Bisi G, Guarino GC, Oradei A, Littarru GP (1992) Mechanism of action of coenzyme Q10 in essential hypertension. Curr Ther Res Clin Exp 51:668–672
Folkers K, Vadhanavikit S, Mortensen SA (1985) Biochemical rationale and myocardial tissue data on the effective therapy of cariomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 82:901–904
Judy WV, Folkers K, Hall JD (1991) Improved long-term survival in coenzyme Q10 treated congestive heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, Yamagami T (eds) Biomedical and clinical aspects of coenzyme Q, vol 6. Elsevier, Amsterdam, pp 291–2989
Kitamura N, Yamaguchi A, Otaki M, Sawatani O, Minoji T Tamuta H, Atobe M (1984) Myocardial tissue level of coenzyme Q10 in patients with cardiac failure. In: Folkers K, Yamamura Y (eds) Biochemical and clinical aspects of coenzyme Q, vol 4. Elsevier, Amsterdam, pp 243–2597
Kupper W (1991) Interrupting the adaptive changes in congestive heart failure. Am J Cardiol 67:20C–22C
Langsjoen PH, Vadhanavikit S, Folkers K (1985) Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and cross-over trial with coenzyme Q10. Proc Natl Acad Sci USA 87:4240–4244
Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T Langsjoen P (1988) Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Kim Wochenschr 66:583–590
Langsjoen PH, Langsjoen PH, Folkers K (1990) Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 65:521–523
Lenaz G, Battino M, et al (1990) Studies on the role of ubiquinone in the control of the mitochondrial respiratory chain. Free Rad Res Comms 8:317–327
Mitchell P (1991) The vital protomotive role of coenzyme Q. In: Folkers K, Yamamura Y, Littarru GP (eds) Biomedical and clinical aspects of coenzyme Q, vol 6. Elsevier, Amsterdam, pp 3–10
Paciaroni E, Ursini T, Gambini C, Littarru GP (1990) Double blind clinical experience for the therapeutic management in the elderly. Cardiologia 12 [Suppl. 1]: 529–535
Poggesi L, Galanti G. Comeglio M, Toncelli L, Vinci M (1991) Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res 49:878–886
Wexler LF (1990) Metabolic consideration in excitation-contraction-relaxation coupling. Heart Failure 3:251
Author information
Authors and Affiliations
Additional information
on behalf of the CoQ10 Drug Surveillance Investigators
The investigators participating in the CoQ10 Drug Surveillance Study are listed in the “Appendix”
Rights and permissions
About this article
Cite this article
Baggio, E., Gandini, R., Plancher, A.C. et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). Clin Investig 71 (Suppl 8), S145–S149 (1993). https://doi.org/10.1007/BF00226857
Issue Date:
DOI: https://doi.org/10.1007/BF00226857